title: Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial.
abstract: BACKGROUND
  Chronic venous disorders (CVD) is estimated to affect 30% to 50% of women and 10% to 30% of men. The most widely prescribed treatment for CVD worldwide is micronized purified flavonoid fraction 500 mg (MPFF). The aim of this clinical trial was to develop a new once daily 1000-mg oral suspension of MPFF.
  
  
  METHODS
  In an international, randomized, double-blind, parallel-group study, symptomatic individuals classified CEAP C0s to C4s were randomized in either treatment arm and treated for 8 weeks. Lower limb symptoms (discomfort, pain and heaviness) were assessed using Visual Analog Scales (VAS), and quality of life (QoL) was measured with the CIVIQ-20 Questionnaire.
  
  
  RESULTS
  A total of 1139 patients were included in the study. Both MPFF treatment regimens were well tolerated and associated with a significant reduction in lower limb symptoms. A non-inferiority of MPFF 1000-mg oral suspension once daily compared to MPFF 500-mg tablet twice daily (P<0.0001) was found for lower limb discomfort (-3.33 cm for MPFF 1000 mg and -3.37 cm for MPFF 500 mg), leg pain (-3.27 cm for MPFF 1000 mg and -3.31 cm for MPFF 500 mg) and leg heaviness (-3.41 cm for MPFF 1000 mg and -3.46 cm for MPFF 500 mg). The patients' QoL was improved by about 20 points on the CIVIQ scale in both groups (19.33 points for MPFF 1000 mg and 20.28 points for MPFF 500 mg).
  
  
  CONCLUSIONS
  MPFF 1000-mg oral suspension and MPFF 500-mg tablets treatments were associated with similar reductions in lower limb symptoms and QoL improvement. The new once daily MPFF1000-mg oral suspension has a similar safety profile to two tablets of MPFF 500 mg, with the advantage of one daily intake, potentially associated with improved patient adherence and easier CVD management.
authors.affiliation: Grenoble University Hospital, Grenoble, France - pcarpentier@chu-grenoble.fr.
authors.forename: Patrick
authors.initials: P
authors.lastname: Carpentier
authors.affiliation: Service of Vascular Surgery and Angiology, Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil.
authors.forename: Bonno
authors.initials: B
authors.lastname: van Bellen
authors.affiliation: Department for Cardiology and Angiology, General Faculty Hospital.
authors.forename: Debora
authors.initials: D
authors.lastname: Karetova
authors.affiliation: st Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: Harunarashid
authors.initials: H
authors.lastname: Hanafiah
authors.affiliation: National University of Malaysia, Kuala Lumpur, Malaysia.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Enriquez-Vega
authors.affiliation: National Autonomous University of Mexico, Mexico City, Mexico.
authors.forename: Alexander
authors.initials: A
authors.lastname: Kirienko
authors.affiliation: Department of Surgery, Faculty of Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
authors.forename: Andrej
authors.initials: A
authors.lastname: Dzupina
authors.affiliation: Angiologická Ambulancia Alian, Bardejov, Slovakia.
authors.forename: Miso
authors.initials: M
authors.lastname: Sabovic
authors.affiliation: Department of Vascular Diseases, University Clinical Center of Ljubljana, Ljubljana, Slovenia.
authors.forename: Lourdes
authors.initials: L
authors.lastname: Reina Gutierrez
authors.affiliation: Department of Angiology and Vascular Surgery, Hospital de la Cruz Roja, Madrid, Spain.
authors.forename: Somboom
authors.initials: S
authors.lastname: Subwongcharoen
authors.affiliation: Rajavithi Hospital, Bangkok, Thailand.
authors.forename: Hasan
authors.initials: H
authors.lastname: Tüzün
authors.affiliation: Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Maggioli
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007391:International Cooperation; D035002:Lower Extremity / Q000098:blood supply* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D059408:Pain Management; D010147:Pain Measurement; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D055815:Young Adult
chemical_list: D005419:Flavonoids